Home > Press release

 

 

ARCHIVE PRESS RELEASE
Chiesi Group communicates that it is not involved in the events concerning the Holostem company
05 Dicembre 2022
Chiesi Group endorses the Manifesto Against Gender-Based Violence
28 Novembre 2022
Chiesi Group’s new Biotech Center of Excellence brings the future of medicine to Parma
21 Novembre 2022
Chiesi Group and Aptar partner to bring to market Disease Management Platform for Patients with Asthma and COPD
18 Ottobre 2022
Chiesi is recertified as a B Corp and sets new tougher objectives for action by 2025
22 Settembre 2022
Chiesi Group brings together experts to discuss care for respiratory patients and presents a new treatment option for COPD at ERS Congress
05 Settembre 2022
Chiesi announces the departure of Ugo Di Francesco as CEO of the Group
31 Agosto 2022
First carbon minimal pMDI is on track with the goal to benefit patients and planet
27 Luglio 2022
Chiesi tracks actions taken for a healthier, more sustainable future
14 Luglio 2022
Chiesi acquires pioneering therapeutic monoclonal antibodies portfolio against EMAP II as potential treatment for PAH
02 Maggio 2022
© 2025 CHIESI Farmaceutici S.p.A.
VAT IT 01513360345
Company's Capital: Euro 75.000.000
Companies Register Office - Parma N.15739
REA: 159271

PHARMACOVIGILANCE

TO REPORT ADVERSE DRUG EVENTS/REACTIONS PLEASE CLICK HERE


follow us on: